Abstract:Activated T cells undergo metabolic reprogramming to meet anabolic, differentiation, and functional demands. Glutamine supports many processes in activated T cells, and inhibition of glutamine metabolism alters T cell function in autoimmune disease and cancer. Multiple glutamine-targeting molecules are under investigation, yet the precise mechanisms of glutamine-dependent CD8 T cell differentiation remain unclear. We show that distinct strategies of glutamine inhibition by glutaminase-specific inhibition with small molecule CB-839, pan-glutamine inhibition with 6-diazo-5-oxo-l-norleucine (DON), or by glutamine-depleted conditions (No Q) produce distinct metabolic differentiation trajectories in murine CD8 T cells. T cell activation with CB-839 treatment had a milder effect than did DON or No Q treatment. A key difference was that CB-839-treated cells compensated with increased glycolytic metabolism, whereas DON and No Q-treated cells increased oxidative metabolism. However, all glutamine treatment strategies elevated CD8 T cell dependence on glucose metabolism, and No Q treatment caused adaptation toward reduced glutamine dependence. DON treatment reduced histone modifications and numbers of persisting cells in adoptive transfer studies, but those T cells that remained could expand normally upon secondary Ag encounter. In contrast, No Q-treated cells persisted well yet demonstrated decreased secondary expansion. Consistent with reduced persistence, CD8 T cells activated in the presence of DON had reduced ability to control tumor growth and reduced tumor infiltration in adoptive cell therapy. Overall, each approach to inhibit glutamine metabolism confers distinct effects on CD8 T cells and highlights that targeting the same pathway in different ways can elicit opposing metabolic and functional outcomes.

Glutaminolysis of CD4+T Cells: A Potential Therapeutic Target in Viral Diseases

Glutaminolysis of CD4+ T Cells: A Potential Therapeutic Target in Viral Diseases

Glutaminolysis and peripheral CD4+ T cell differentiation: from mechanism to intervention strategy

Glutamine metabolism: from proliferating cells to cardiomyocytes

Glutamate Dehydrogenase 1: A Novel Metabolic Target in Inhibiting Acute Myeloid Leukaemia Progression.

Glutaminolysis is a Potential Therapeutic Target for Kidney Diseases

Elevated glutamate impedes anti-HIV-1 CD8 + T cell responses in HIV-1-infected individuals on antiretroviral therapy

Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies

Targeting cellular adaptive responses to glutaminolysis perturbation for cancer therapy

Metabolic Reprogramming in CD8+ T Cells During Acute Viral Infections

Intracellular Redox-Modulated Pathways as Targets for Effective Approaches in the Treatment of Viral Infection

Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells

A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment

Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment

Targeting glutamine metabolism as a therapeutic strategy for cancer

The emerging roles of glutamine amidotransferases in metabolism and immune defense

Utilization of Stable Isotope Tail-Vein Infusion to Assess Glutamine Utilization by Physiologically Activated CD8+ T cells in vivo

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer

The role of glutamate receptors in the regulation of the tumor microenvironment

Glutamine metabolism in cancers: Targeting the oxidative homeostasis